This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Enzon Announces Publication Of Preclinical Study Data Of PEG-SN38 In Pediatric Neuroblastoma

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company’s novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma. The data were published in the October 1, 2010 issue of Clinical Cancer Research (Pastorino, F. et al, volume 16, number 9, pp. 4809-4821).

“PEG-SN38 demonstrated complete and durable tumor regression in a series of experimental models that were designed to reflect the clinical progression of neuroblastoma in pediatric patients,” said Ivan Horak, M.D., Enzon’s President of Research and Development and Chief Scientific Officer, and one of the study’s authors. “Neuroblastoma is the second-most common pediatric solid tumor, with a five year-survival rate of only 25 percent. The limited efficacy and significant toxicities associated with currently available treatment options underscore the need for new and better therapies. The present findings form the basis for our ongoing Phase I study of PEG-SN38 in pediatric patients with solid tumors which may include patients with neuroblastoma.”

The preclinical study was designed to assess the antitumor activity of PEG-SN38 relative to CPT-11, a chemotherapeutic drug that is currently used in the clinical treatment of neuroblastoma and other solid tumors. CPT-11 has shown activity against neuroblastoma that has become resistant to standard treatments, and its non-hematological toxicities are considered transient and manageable. However, its limitations include the inconvenience of current daily schedule and gastrointestinal side effects. While direct administration of SN38 may overcome these limitations, its low solubility does not allow formulation in conventional pharmaceutical vehicles that would permit administration to patients. Enzon’s proprietary customized linker-enhanced PEGylation technology allows a soluble, more potent, and longer-lasting version of the drug, which may be administered weekly or once every three weeks.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs